Dr. Reddy's Laboratories (RDY) Competitors $15.37 +0.25 (+1.65%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends RDY vs. TAK, BNTX, TEVA, BGNE, MRNA, VTRS, SMMT, GMAB, SRPT, and CTLTShould you be buying Dr. Reddy's Laboratories stock or one of its competitors? The main competitors of Dr. Reddy's Laboratories include Takeda Pharmaceutical (TAK), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Moderna (MRNA), Viatris (VTRS), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Sarepta Therapeutics (SRPT), and Catalent (CTLT). These companies are all part of the "pharmaceutical products" industry. Dr. Reddy's Laboratories vs. Takeda Pharmaceutical BioNTech Teva Pharmaceutical Industries BeiGene Moderna Viatris Summit Therapeutics Genmab A/S Sarepta Therapeutics Catalent Takeda Pharmaceutical (NYSE:TAK) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations, community ranking and valuation. Do analysts prefer TAK or RDY? Dr. Reddy's Laboratories has a consensus price target of $17.00, indicating a potential upside of 10.61%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe Dr. Reddy's Laboratories is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Dr. Reddy's Laboratories 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk and volatility, TAK or RDY? Takeda Pharmaceutical has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Is TAK or RDY a better dividend stock? Takeda Pharmaceutical pays an annual dividend of $0.53 per share and has a dividend yield of 4.0%. Dr. Reddy's Laboratories pays an annual dividend of $0.08 per share and has a dividend yield of 0.5%. Takeda Pharmaceutical pays out 91.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Dr. Reddy's Laboratories pays out 12.7% of its earnings in the form of a dividend. Does the MarketBeat Community prefer TAK or RDY? Dr. Reddy's Laboratories received 221 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 59.33% of users gave Dr. Reddy's Laboratories an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote. CompanyUnderperformOutperformTakeda PharmaceuticalOutperform Votes10056.82% Underperform Votes7643.18% Dr. Reddy's LaboratoriesOutperform Votes32159.33% Underperform Votes22040.67% Does the media favor TAK or RDY? In the previous week, Dr. Reddy's Laboratories had 4 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 6 mentions for Dr. Reddy's Laboratories and 2 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.59 beat Dr. Reddy's Laboratories' score of 0.58 indicating that Takeda Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of TAK or RDY? 9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is TAK or RDY more profitable? Dr. Reddy's Laboratories has a net margin of 17.81% compared to Takeda Pharmaceutical's net margin of 6.49%. Dr. Reddy's Laboratories' return on equity of 18.53% beat Takeda Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Takeda Pharmaceutical6.49% 10.00% 4.78% Dr. Reddy's Laboratories 17.81%18.53%13.01% Which has stronger earnings & valuation, TAK or RDY? Takeda Pharmaceutical has higher revenue and earnings than Dr. Reddy's Laboratories. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTakeda Pharmaceutical$4.55T0.01$994.06M$0.5822.59Dr. Reddy's Laboratories$299.87B0.04$668M$0.6324.40 SummaryDr. Reddy's Laboratories beats Takeda Pharmaceutical on 15 of the 20 factors compared between the two stocks. Ad Porter & CompanyWhat Joe Biden got rightAnyone with a brain knows Joe Biden failed this country from day one. But, even I must admit there is one thing the Biden administration did right. I call this tech, “The AI Keystone.” It’s the number-one way to capitalize on the trillion-dollar artificial intelligence market.check out my new report. Get Dr. Reddy's Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RDY vs. The Competition Export to ExcelMetricDr. Reddy's LaboratoriesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$12.83B$6.57B$5.02B$19.19BDividend Yield0.55%3.09%4.87%3.57%P/E Ratio24.5510.55135.2041.24Price / Sales0.04194.011,120.3117.58Price / Cash14.2657.1640.5821.28Price / Book3.805.104.755.32Net Income$668M$151.51M$118.50M$989.67M7 Day Performance6.29%-2.16%-1.83%-3.59%1 Month Performance9.86%-2.91%12.27%-2.48%1 Year Performance15.06%13.93%31.72%13.87% Dr. Reddy's Laboratories Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RDYDr. Reddy's Laboratories1.8355 of 5 stars$15.37+1.7%$17.00+10.6%+15.8%$12.83B$299.87B24.5527,048Analyst DowngradeNews CoverageGap UpTAKTakeda Pharmaceutical4.3853 of 5 stars$13.34-0.6%N/A-4.3%$42.45B$28.20B23.1449,281BNTXBioNTech1.886 of 5 stars$114.99-4.5%$140.76+22.4%+10.0%$27.34B$3.04B-56.016,133TEVATeva Pharmaceutical Industries1.874 of 5 stars$16.72+1.3%$19.67+17.6%+112.2%$18.94B$16.77B-19.7937,851Analyst DowngradeOptions VolumeNews CoveragePositive NewsBGNEBeiGene2.7933 of 5 stars$176.52-1.6%$253.69+43.7%+0.7%$17.20B$2.46B-21.7710,600MRNAModerna4.3399 of 5 stars$41.59-0.6%$79.50+91.2%-54.3%$16.00B$5.06B-7.195,600Analyst DowngradeVTRSViatris2.0808 of 5 stars$12.74+0.9%$13.67+7.3%+19.8%$15.21B$15.05B-17.0738,000News CoverageSMMTSummit Therapeutics3.2635 of 5 stars$18.21+2.1%$33.33+83.0%+636.9%$13.43B$700,000.00-63.68105News CoverageGap DownGMABGenmab A/S4.2933 of 5 stars$20.21+0.2%$45.20+123.7%-33.5%$13.37B$19.84B19.582,204High Trading VolumeSRPTSarepta Therapeutics4.8819 of 5 stars$127.00+2.7%$178.71+40.7%+31.8%$12.13B$1.64B98.971,314Analyst ForecastPositive NewsCTLTCatalent2.7791 of 5 stars$63.47+0.6%$63.40-0.1%N/A$11.52B$4.38B-27.9116,900High Trading Volume Related Companies and Tools Related Companies Takeda Pharmaceutical Alternatives BioNTech Alternatives Teva Pharmaceutical Industries Alternatives BeiGene Alternatives Moderna Alternatives Viatris Alternatives Summit Therapeutics Alternatives Genmab A/S Alternatives Sarepta Therapeutics Alternatives Catalent Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:RDY) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Reddy's Laboratories Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Dr. Reddy's Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RDY Stock Alerts